

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Norucholic acid for treating primary sclerosing cholangitis [ID6583]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

Stakeholders noted that:

- Access to PSC care is concentrated in specialist centres.
- the importance of equitable access for young people.
- PSC disproportionately affects men compared with women.
- EQ-5D would not be able to capture symptoms of PSC.

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

- variations in access to NHS care itself is not an equality issue that could be addressed within a NICE technology appraisal.
- Issues related to differences in prevalence cannot be addressed in a technology appraisal.
- The use of EQ-5D is a methodological issue.

However, where relevant and appropriate, the committee may consider whether its recommendation would have a different impact on people protected by the equality legislation (such as age and gender) than on the wider population. If robust evidence showed that EQ-5D is not able to

capture symptoms related to PSC, the committee may consider whether supplementary evidence (for example condition-specific measures) is appropriate.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No

Approved by Principal Technical Adviser (name): Adam Brooke

Date: 04/06/2026